NTRK Fusion Gene Positive Advanced Solid Tumors Market

NTRK Fusion Gene Positive Advanced Solid Tumors Market : Global Industry Analysis 2015-2019 and Opportunity Assessment 2020-2030

  • Ongoing
  • July 2020
  • REP-GB-11303
  • PDF PPT EXCEL
NTRK Fusion Gene Positive Advanced Solid Tumors Market
  • SELECT LICENSE TYPE :

  • US$5,000
  • US$7,500
  • US$10,000

This NTRK Fusion Gene Positive Advanced Solid Tumors market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving NTRK Fusion Gene Positive Advanced Solid Tumors market.

A patient with tumors who has mutated genes NTRK is called NTRK fusion gene positive tumors. Although NTRK fusions are rare and account to nearly 1% of solid tumors, the exact frequency is quite unclear. DNA Next Generation Sequencing (NSG) technology is a precise method to detect NTRK fusion genes. It has high specificity and sensitivity. It can detects gene partners that may have high clinical implications in treatment. Currently Commercialized techniques such as DNA NGS panels, Foundation One may not detect NTRK fusions.  

NTRK Fusion Gene Positive Advanced Solid Tumors Market: Drivers and Restraints

NTRK fusions has higher prevalence rate as they are found in most of solid cancer types. This is expected to drives NTRK fusion gene positive advanced solid tumors market. NTRK is a unique gene which has implications in many types of cancers and the development of latest drugs is expected to drive NTRK fusion gene positive advanced solid tumors market. However, Poor healthcare infrastructure and high costs associated with genetic screening of NTRK fusion genes may hamper growth of NTRK fusion gene positive advanced solid tumors market in the future. 

Market Growth Analysis

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

COVID -19 : Impact Analysis

Request the coronavirus impact analysis across industries and markets

Request Covid -19 Impact

NTRK Fusion Gene Positive Advanced Solid Tumors Market: Overview

The global NTRK fusion gene positive advanced solid tumors market is estimated to show rapid growth over forecast period owing to technical advancements. Early screening and detection of NTRK mutation genes in people will contribute to NTRK fusion gene positive advanced solid tumors market. Global NTRK fusion gene positive advanced solid tumors market has high potential due to development of novel therapeutics in near future for treating different types of cancers. Recently in 2019, FDA approved NTRK inhibitors like Entrectinib manufactured by Genentech Inc., for effective treatment of NTRK fusion gene positive advanced solid tumors.

NTRK Fusion Gene Positive Advanced Solid Tumors Market: Regional Overview

The global NTRK fusion gene positive advanced solid tumors market is expected to be dominated by North America owing to rising cancer clinical research and development activities. Latin America market is emerging in NTRK fusion gene positive advanced solid tumors market due to increased spending on healthcare infrastructure. Europe market is expected to be the second most growing region in the global NTRK fusion gene positive advanced solid tumors market owing to early diagnosis and treatment adoption. NTRK fusion gene positive advanced solid tumors market in East Asia and South Asia is expected to show significant growth due to improving healthcare infrastructure. Middle East and Africa market is expected to be least lucrative region in the NTRK fusion gene positive advanced solid tumors market due to poor healthcare facilities and less disease screening facilities.

NTRK Fusion Gene Positive Advanced Solid Tumors Market: Key Players

Examples of some of the market participants in NTRK fusion gene positive advanced solid tumors market identified across the value chain includes Bayer A.G., Merck & Co., Inc., F. Hoffmann-La Roche AG, Glaxosmithkline plc, Pfizer Inc., Plexxikon, Daiichi Sankyo Company Limited, Deciphera Pharmaceuticals, Inc., Eli Lilly and company, Exelixis, Inc., Cephalon, Inc., and others.

The research report on NTRK fusion gene positive advanced solid tumors market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and, statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on NTRK fusion gene positive advanced solid tumors market provides analysis and information according to market segments such as geographies, application, and end user.  

The report covers exhaust analysis on NTRK Fusion Gene Positive Advanced Solid Tumors Market:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Report on NTRK Fusion Gene Positive Advanced Solid Tumors Market includes regional analysis:

  • North America (U.S., Canada)
  • Latin America (Brazil, Mexico, Argentina)
  • Europe (Germany, Italy, France, U.K, Spain, Russia)
  • East Asia (China, Japan, South Korea)
  • South Asia (India, ASEAN)
  • Oceania (Australia, New Zealand)
  • Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report on NTRK fusion gene positive advanced solid tumors market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key NTRK Fusion Gene Positive Advanced Solid Tumors Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

NTRK Fusion Gene Positive Advanced Solid Tumors Market: Segmentation

The global NTRK fusion gene positive advanced solid tumors market is classified on the basis of Indication and End User.

Based on indication, NTRK fusion gene positive advanced solid tumors market is segmented into the following:

  • NTRK 1 Fusion Tumors
  • NTRK 2 Fusion Tumors
  • NTRK 3 Fusion Tumors

Based on end user, NTRK fusion gene positive advanced solid tumors market is segmented into the following:

  • Hospitals
  • Specialty Clinics
  • Cancer Centers
  • Cancer Research Institutes

Report on NTRK Fusion Gene Positive Advanced Solid Tumors Market highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current, and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying NTRK Fusion Gene Positive Advanced Solid Tumors Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the NTRK Fusion Gene Positive Advanced Solid Tumors Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch
Harish Tiwari

Harish Tiwari

Global Head - Business Development

Akshay Godge

Akshay Godge

Client Partner - Global Business Development

Our Clients


Request Sample Request customization Request Methodology